Abstract
What is known and objective: High-dose methotrexate (HD-MTX) is associated with a plethora of adverse drug reactions and potential drug interactions (DIs). But there is a paucity of information regarding the safety of co-administering primaquine with HD-MTX. Case summary: A 65-year-old male patient was diagnosed with mantle cell lymphoma (MCL) with CNS involvement and treated with three cycles of IV HD-MTX. His case was further complicated by fungal pneumonia treated with primaquine during cycle-2. Serial blood sampling and subsequent population pharmacokinetics (PK) modelling suggests a possible distribution-mediated DI between the two drugs. What is new and conclusion: This is the first case report to highlight the safe co-administration of MTX and primaquine, despite a possible PK interaction.
| Original language | English |
|---|---|
| Pages (from-to) | 800-804 |
| Number of pages | 5 |
| Journal | Journal of Clinical Pharmacy and Therapeutics |
| Volume | 44 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Oct 2019 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- clinical pharmacokinetics
- CNS dissemination
- drug interaction
- hematologic malignancy
- mantle cell lymphoma
- methotrexate
- pharmacokinetics
- primaquine
- safety
- therapeutic drug monitoring
Fingerprint
Dive into the research topics of 'A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver